Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
View original at globenewswire.comAmphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-V…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
SMARCA4 mutations are observed in >5% NSCLC patients and are associated with poor prognosis and advanced disease
60% confidenceAmphista has achieved compound profiles that uniquely position them to deliver class-leading SMARCA2 degraders for the treatment of SMARCA4-mutant NSCLC
60% confidenceTEAD degraders demonstrate exceptional on-pathway selectivity profiles and exhibit the expected Hippo signalling modulation
60% confidenceFive-year survival rates for AML remain at just 33% and is the cause of death for an estimated 130,000 patients globally each year
60% confidenceDegradation of BRD9 releases the differentiation block and leads to the differentiation and death of AML blasts
60% confidenceSMARCA2 degraders achieve near complete selectivity over SMARCA4 in a SMARCA4 WT model
60% confidenceOptimised SMARCA2 compounds can deliver fast, deep degradation of SMARCA2 as demonstrated in-vivo in a disease-relevant SMARCA4 mutant model
60% confidenceAmphista is a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue degraders
60% confidenceAldehyde-mediated degrons are a viable strategy for targeted protein degradation, enabling rational design of degraders that hijack endogenous protein quality control machinery for precision medicine applications
60% confidenceSMARCA2 degraders potently drive >95% SMARCA2 degradation within 4 hours, resulting in deep suppression of biomarkers KRT80 and PLAU in vitro
60% confidenceSMARCA2 Targeted Glues induce degradation via selective recruitment of DCAF16 and covalent interaction with a single DCAF16 cysteine residue
60% confidenceAmine-based TEAD degrader scaffolds undergo extracellular conversion to reactive aldehyde species, which mediate covalent engagement of FBXO22 C326, triggering TEAD proteasomal degradation
60% confidenceTEAD degraders achieve enhanced degradation profiles compared to previously reported FBXO22-targeting approaches
60% confidence